查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718341

按产品类型、最终用户和应用程式分類的诊断市场—2025 年至 2030 年全球预测

Diagnostic Substances Market by Product Type, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年诊断市场价值将达到 1,783.6 亿美元，2025 年将成长至 1,895.3 亿美元，复合年增长率为 6.48%，到 2030 年将达到 2,599.9 亿美元。

主要市场统计数据
基准年2024年 1783.6亿美元
预计2025年 1895.3亿美元
预测年份 2030 2599.9亿美元
复合年增长率（%） 6.48%

诊断材料是现代医学创新的核心，推动疾病检测和病患管理的进步。在科技快速进步和临床需求不断发展的时代，诊断技术发生了重大变化。诊断市场的特点是研究活跃、仪器、测试和试剂发展强劲，对更快、更准确的诊断解决方案的需求不断增加。

诊断技术的进步不仅证明了科学的独创性，也体现了全球对个人化和精准医疗的追求。本报告深入探讨了综合诊断领域，重点关注市场趋势、突破性技术以及自动化、经济高效平台的新兴角色。它说明了严格的验证通讯协定、监管标准以及新产品类型和最终用户需求之间的相互关係等关键因素。

透过结合大量研究数据和顶尖专家的见解，本简报对市场现状和未来方向进行了均衡的检验。了解产品创新的根本驱动力对于医疗保健组织和製造商保持领先地位至关重要。它着重于基于证据的分析，旨在提供清晰且引人入胜的介绍，为后续章节的进一步探索奠定基础。

改变诊断市场

诊断领域发生了变革性的变化，重新定义了市场边界并为临床和研究应用开闢了新的途径。这些变化体现在数位技术的快速融合、分子诊断的复杂化以及各种检测所用试剂的演变。

一个显着的趋势是从传统的诊断方法转向高度自动化的系统，从而提高了速度和准确性。这种转型变化不仅是由技术主导的，也受到全球日益重视早期和准确诊断的影响。次世代定序和聚合酵素链锁反应（PCR）技术的进步使得人们能够更深入地研究遗传标记和疾病途径，促进个人化医疗的突破。

数位融合在重塑市场动态也发挥关键作用。云端基础的数据管理、影像分析中的人工智慧和机器学习演算法使实验室能够处理和解释大量诊断数据。这些创新可加快诊断时间、提高可靠性并优化高通量环境中的工作流程。仪器、生物检测和试剂化学的融合产生了一个强大、多功能且不断适应现代医疗保健和研究需求的平台。

目前市场的特点是采用整体方法，製造商、临床医生和研究人员共同开发可扩展且可靠的诊断解决方案。这种相互依存的生态系统不仅激发了创新，而且将改善患者照护作为首要任务，有效地将诊断材料转变为未来医疗保健议程的重要工具。

关键细分洞察－产品、最终用户、应用

在诊断市场中，细分对于了解推动需求的多样化产品、使用者和应用起着至关重要的作用。产品类型细分为仪器、套件和分析以及试剂。例如，设备部分进一步分为分析仪器、影像仪器和分子诊断仪器。深入研究分子诊断设备，我们看到次世代定序技术和 PCR 机器的强劲成长，这两者都彻底改变了复杂遗传讯息的分析方式。同时，套件和检测方法包括 ELISA套件、横向流动化验、PCR套件和快速检测套组，每种试剂盒都针对特定的诊断需求量身定制，并在不同的法律规范下运行。同样重要的是试剂，包括抗体试剂、抗原试剂、酵素、核酸试剂、重组蛋白等，它们构成了诊断检测的骨干。

市场也按最终用户进行细分，从诊断和法医学实验室到医院诊所、就地检验设施以及研究和学术机构。每个最终用户都有独特的要求，因此需要能够适应不同环境的客製化解决方案。例如，诊断实验室受益于高通量自动化系统，而 POC 测试设施则需要可携式、快速且易于使用的仪器。这种细分凸显了对能够适应各种临床和研究工作流程的多功能产品平台的需求。

此外，基于应用的细分将市场分为临床诊断、法医学和研究。临床诊断部分进一步细分为循环系统、内分泌学、感染疾病、神经科和肿瘤学等专业部分。法医学部门专注于血液样本检测、DNA分析和毒理学筛检等能力。同时，研究部分涵盖药物发现、基因体学研究和蛋白质体学研究。这种多层次的细分结构不仅凸显了市场的复杂性，也凸显了诊断技术满足多样化且快速发展的科学和临床期望的适应性。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 慢性病盛行率的上升推动了全球对诊断的需求
      • 消费者对准确、快速诊断测试选项的认识和需求不断提高
      • 人口老化需要更频繁、更多样化的诊断检测服务
    • 限制因素
      • 供应链中断影响诊断产品的可用性和分发
    • 机会
      • 诊断创新的投资和资金快速成长
      • 诊断技术的进步有助于改善物质的使用和分析
    • 任务
      • 诊断药物处置中的环境永续性问题
  • 市场区隔分析
    • 产品类型：对高精度、高效率诊断分析仪的需求不断增长
    • 用途：增加诊断剂在临床诊断中的使用，以评估心臟相关疾病
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 诊断市场（依产品类型）

  • 介绍
  • 装置
    • 分析仪
    • 影像设备
    • 分子诊断设备
      • 下一代定序
      • PCR仪
  • 套件和检测试剂
    • ELISA套件
    • 横向流动化验
    • PCR套件
    • 快速检测套组
  • 试剂
    • 抗体试剂
    • 抗原试剂
    • 酵素
    • 核酸试剂
    • 重组蛋白

第七章 诊断市场（依最终使用者划分）

  • 介绍
  • 诊断实验室
  • 法医学实验室
  • 医院和诊所
  • 就地检验实验室
  • 研究和学术机构

第 8 章 诊断市场（按应用）

  • 介绍
  • 临床诊断
    • 心臟病学
    • 内分泌学
    • 感染疾病
    • 神经病学
    • 肿瘤学
  • 法医学
    • 血液样本检测
    • DNA分析
    • 毒理学
  • 研究
    • 药物研发
    • 基因组学研究
    • 蛋白质体学调查

第九章美洲诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第 10 章：亚太诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 11 章欧洲、中东和非洲的诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Asuragen, Inc. by Bio-Techne Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioLytical Laboratories
  • bioMerieux SA
  • Cepheid by Danaher Corporation
  • DiaSorin SpA
  • Enzo Biochem, Inc.
  • Hitachi Ltd.
  • Hoffmann-La Roche AG
  • Hologic Inc.
  • HyTest Ltd.
  • Illumina Inc.
  • Merck KGaA
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • Qiagen NV
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens AG
  • Sysmex Corporation by TOA Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C040C

The Diagnostic Substances Market was valued at USD 178.36 billion in 2024 and is projected to grow to USD 189.53 billion in 2025, with a CAGR of 6.48%, reaching USD 259.99 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 178.36 billion
Estimated Year [2025] USD 189.53 billion
Forecast Year [2030] USD 259.99 billion
CAGR (%) 6.48%

Diagnostic substances are at the very heart of modern healthcare innovation, driving advances in disease detection and patient management. In an era defined by rapid technological progress and evolving clinical needs, diagnostic substances have undergone remarkable changes. The market is marked by dynamic research, robust development in instruments, tests, and reagents, and an ever-increasing demand for faster, more accurate diagnostic solutions.

The evolution of diagnostic substances is not only a testament to scientific ingenuity but also a reflection of the global commitment to personalized medicine and precision health care. This report delves into the comprehensive landscape of diagnostic substances with an emphasis on market trends, breakthrough technologies, and the emerging role of automated, cost-effective platforms. The narrative is built around key factors such as rigorous validation protocols, regulatory standards, and interconnections between emerging product types and end-user demands.

By synthesizing extensive research data with insights from leading experts, this overview presents a balanced examination of current market conditions and future directions. As healthcare organizations and manufacturers seek to stay ahead, understanding the underlying dynamics that drive product innovation is essential. With an emphasis on evidence-based analysis, the discussion aims to provide a clear, engaging introduction that serves as the foundation for further exploration in subsequent sections.

Transformative Shifts in the Diagnostic Substances Market Landscape

The landscape of diagnostic substances has witnessed transformative shifts that have redefined market boundaries and opened new avenues for clinical and research applications. These shifts are evident in the rapid integration of digital technologies, the refinement of molecular diagnostics, and the evolution of reagents used in a variety of assays.

One of the striking trends is the move from traditional diagnostic approaches to highly automated systems, which have enhanced both speed and precision. This transformative change is not only technology-driven but also influenced by a growing global emphasis on early and accurate diagnosis. Advancements in next-generation sequencing and polymerase chain reaction (PCR) technologies have allowed for a deeper investigation into genetic markers and disease pathways, facilitating breakthroughs in personalized medicine.

Digital integration has also played a key role in reshaping market dynamics. Cloud-based data management, artificial intelligence in image analysis, and machine learning algorithms have empowered laboratories with the capability to process and interpret vast amounts of diagnostic data. These innovations have led to a reduction in diagnostic turnaround time, improved reliability, and optimized workflows in high-throughput environments. The convergence of instrumentation, bioassays, and reagent chemistries has resulted in platforms that are both robust and versatile, adapting continuously to the demands of modern healthcare and research.

The market is now characterized by a holistic approach where manufacturers, clinicians, and researchers work in tandem to develop scalable and reliable diagnostic solutions. This interdependent ecosystem not only fuels innovation but also ensures that improvements in patient care remain a top priority, effectively transforming diagnostic substances into indispensable tools for future healthcare initiatives.

Key Segmentation Insights: Product, End-User, and Application

Within the diagnostic substances market, segmentation plays a pivotal role in understanding the diverse range of products, users, and applications that drive demand. A granular breakdown by product type covers instruments, kits & assays, and reagents. The instruments segment, for instance, is further dissected into analyzers, imaging equipment, and molecular diagnostic instruments. Digging deeper into molecular diagnostic instruments reveals strong growth in next-generation sequencing technologies and PCR machines, both of which have revolutionized the way complex genetic information is analyzed. Kits and assays, on the other hand, include ELISA kits, lateral flow assays, PCR kits, and rapid test kits, each tailored to meet specific diagnostic needs and operating under varied regulatory frameworks. Equally critical are the reagents, encompassing antibody reagents, antigen reagents, enzymes, nucleic acid reagents, and recombinant proteins which form the backbone of diagnostic assays.

The market is also segmented by end-users, ranging from diagnostic laboratories and forensic laboratories to hospitals & clinics, point-of-care testing facilities, and research & academic institutes. Each of these end-users has unique requirements, thus necessitating tailored solutions that can adapt to different environments. For instance, diagnostic laboratories benefit from high-throughput automated systems, while point-of-care testing facilities demand portable, swift, and easy-to-use instruments. This segmentation underscores the need for versatile product platforms capable of adapting to various clinical and research workflows.

Furthermore, application-based segmentation divides the market into clinical diagnostics, forensic, and research. Within clinical diagnostics, there is a further subdivision into specialties such as cardiology, endocrinology, infectious diseases, neurology, and oncology. In the forensic domain, the focus is on functionalities like blood sample testing, DNA analysis, and toxicology screening. The research segment, meanwhile, is targeted towards drug discovery, genomics research, and proteomics research. This layered segmentation structure not only highlights the complexity of the market but also underscores the adaptability of diagnostic substances in meeting diverse, rapidly evolving scientific and clinical expectations.

Based on Product Type, market is studied across Instruments, Kits & Assays, and Reagents. The Instruments is further studied across Analyzers, Imaging Equipment, and Molecular Diagnostic Instruments. The Molecular Diagnostic Instruments is further studied across Next-Generation Sequencing and PCR Machines. The Kits & Assays is further studied across ELISA Kits, Lateral Flow Assays, PCR Kits, and Rapid Test Kits. The Reagents is further studied across Antibody Reagents, Antigen Reagents, Enzymes, Nucleic Acid Reagents, and Recombinant Proteins.

Based on End-User, market is studied across Diagnostic Laboratories, Forensic Laboratories, Hospitals & Clinics, Point-of-Care Testing Facilities, and Research & Academic Institutes.

Based on Application, market is studied across Clinical Diagnostics, Forensic, and Research. The Clinical Diagnostics is further studied across Cardiology, Endocrinology, Infectious Diseases, Neurology, and Oncology. The Forensic is further studied across Blood Sample Testing, DNA Analysis, and Toxicology. The Research is further studied across Drug Discovery, Genomics Research, and Proteomics Research.

Key Regional Insights: Americas, Europe, Middle East & Africa, Asia-Pacific

Regional dynamics exert a profound influence on the evolution of the diagnostic substances market. The market exhibits distinct trends across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each driven by unique factors ranging from regulatory environments to levels of technological adoption.

In the Americas, particularly in North America, high investment in healthcare infrastructure and a focus on innovation have largely shaped market growth. Advanced research facilities and state-of-the-art diagnostic laboratories have set the pace for technology adoption, leading to robust demand for precision diagnostic tools. Across Europe and in parts of the Middle East and Africa, regulatory support combined with public and private partnerships has accelerated the introduction of next-generation diagnostic platforms. Stringent quality standards and an emphasis on evidence-based medicine have contributed to the steady, albeit diverse, growth in these regions.

The Asia-Pacific region is emerging as a significant growth driver with rapid urbanization, increased healthcare spending, and expanding diagnostic networks. Governments and private entities in these areas are increasingly investing in state-of-the-art diagnostic technologies to meet the rising demand in both clinical and research settings. The drive for local innovation paired with technology transfer from leading global markets has created a fertile ground for market expansion. Taken together, these regional insights indicate that while market strategies may need to be tailored to reflect local conditions, the underlying advancements remain consistently transformative across all territories.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Leading Innovators in Diagnostic Substances

The diagnostic substances market is characterized by the involvement of several pioneering companies whose continual innovation shapes industry trends and future directions. Leading players such as Abbott Laboratories, Agilent Technologies Inc., Asuragen, Inc. by Bio-Techne Corporation, and Becton, Dickinson and Company have been instrumental in advancing diagnostic instruments and assay technologies. Companies like Bio-Rad Laboratories Inc., bioLytical Laboratories, and bioMerieux SA further contribute by developing advanced reagents and testing kits that meet stringent quality standards.

Other notable entities include Cepheid by Danaher Corporation, DiaSorin S.p.A., Enzo Biochem, Inc., Hitachi Ltd., and Hoffmann-La Roche AG, whose research efforts have resulted in breakthrough platforms in molecular diagnostics. Emerging innovators such as Hologic Inc., HyTest Ltd., Illumina Inc., and Merck KGaA continue to push the boundaries of what is achievable in terms of predictive accuracy and diagnostic efficiency. Firms like OraSure Technologies, Inc. and Ortho Clinical Diagnostics have expanded their portfolios to include both high-throughput automated systems and rapid point-of-care solutions.

Further contributions come from Qiagen N.V., Quidel Corporation, Randox Laboratories Ltd., Sekisui Diagnostics, LLC, Siemens AG, Sysmex Corporation by TOA Corporation, and Thermo Fisher Scientific Inc. These companies not only drive technological advancements but also set industry benchmarks in quality control, regulatory compliance, and customer engagement. Together, these key industry players create an ecosystem that is responsive to emerging public health challenges and is ever-prepared to meet the demands of the evolving diagnostic landscape.

The report delves into recent significant developments in the Diagnostic Substances Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Asuragen, Inc. by Bio-Techne Corporation, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioLytical Laboratories, bioMerieux SA, Cepheid by Danaher Corporation, DiaSorin S.p.A., Enzo Biochem, Inc., Hitachi Ltd., Hoffmann-La Roche AG, Hologic Inc., HyTest Ltd., Illumina Inc., Merck KGaA, OraSure Technologies, Inc., Ortho Clinical Diagnostics, Qiagen N.V., Quidel Corporation, Randox Laboratories Ltd., Sekisui Diagnostics, LLC, Siemens AG, Sysmex Corporation by TOA Corporation, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders in Diagnostic Substances

In light of the transformative shifts and nuanced segmentation within the diagnostic substances market, industry leaders are encouraged to adopt a forward-thinking approach. It is essential to invest in research and development initiatives focused on integrating digital technologies with traditional testing modalities, thereby enhancing diagnostic accuracy and speed. Companies should consider strengthening partnerships with academic institutions and specialized research centers to foster innovation through collaborative endeavors.

Optimizing supply chains and bolstering product portfolios with a balanced mix of cutting-edge instruments, robust assays, and high-quality reagents will also be critical. Furthermore, aligning product strategies with regional requirements and regulatory landscapes can unlock new market opportunities. Emphasizing sustainability, operational efficiency, and quality assurance can help ensure that organizations remain competitive in a steadily evolving market environment.

Conclusion and Future Outlook for Diagnostic Substances

The diagnostic substances market is rapidly evolving to meet the challenges of modern healthcare and research environments. Driving forces such as technological innovation, robust segmentation, and dynamic regional shifts are set to influence market trajectories for the foreseeable future. Manufacturers, clinicians, and investors must continuously adapt and leverage state-of-the-art breakthroughs to stay ahead in this competitive landscape.

In essence, the market's ability to integrate diverse diagnostic tools and methodologies into cohesive platforms reflects a broader trend towards personalized medicine and precision diagnostics. As the industry moves forward, the focus on harmonizing product development with evolving clinical needs will undoubtedly catalyze further breakthroughs. Stakeholders who invest in cutting-edge research and strategic collaborations are best positioned to harness the immense potential of these innovations, ensuring long-term success and improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases spurs greater demand for diagnostic substances worldwide
      • 5.1.1.2. Increasing consumer awareness and demand for accurate and rapid diagnostic testing options
      • 5.1.1.3. Growing geriatric population necessitating more frequent and diverse diagnostic testing services
    • 5.1.2. Restraints
      • 5.1.2.1. Supply chain disruptions impacting the availability and distribution of diagnostic substances
    • 5.1.3. Opportunities
      • 5.1.3.1. Surging investments & funding for innovations in diagnostic substances
      • 5.1.3.2. Advancements in diagnostics to enhance efficiency in substance usage and analysis
    • 5.1.4. Challenges
      • 5.1.4.1. Environmental sustainability concerns in the disposal of diagnostic substances
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Rising demand of analyzers for diagnosis with heightened accuracy and efficiency
    • 5.2.2. Application: Growing usage of diagnostic substances in clinical diagnostics for assessing heart-related conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diagnostic Substances Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
    • 6.2.1. Analyzers
    • 6.2.2. Imaging Equipment
    • 6.2.3. Molecular Diagnostic Instruments
      • 6.2.3.1. Next-Generation Sequencing
      • 6.2.3.2. PCR Machines
  • 6.3. Kits & Assays
    • 6.3.1. ELISA Kits
    • 6.3.2. Lateral Flow Assays
    • 6.3.3. PCR Kits
    • 6.3.4. Rapid Test Kits
  • 6.4. Reagents
    • 6.4.1. Antibody Reagents
    • 6.4.2. Antigen Reagents
    • 6.4.3. Enzymes
    • 6.4.4. Nucleic Acid Reagents
    • 6.4.5. Recombinant Proteins

7. Diagnostic Substances Market, by End-User

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Forensic Laboratories
  • 7.4. Hospitals & Clinics
  • 7.5. Point-of-Care Testing Facilities
  • 7.6. Research & Academic Institutes

8. Diagnostic Substances Market, by Application

  • 8.1. Introduction
  • 8.2. Clinical Diagnostics
    • 8.2.1. Cardiology
    • 8.2.2. Endocrinology
    • 8.2.3. Infectious Diseases
    • 8.2.4. Neurology
    • 8.2.5. Oncology
  • 8.3. Forensic
    • 8.3.1. Blood Sample Testing
    • 8.3.2. DNA Analysis
    • 8.3.3. Toxicology
  • 8.4. Research
    • 8.4.1. Drug Discovery
    • 8.4.2. Genomics Research
    • 8.4.3. Proteomics Research

9. Americas Diagnostic Substances Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diagnostic Substances Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diagnostic Substances Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Roche launched cobas Mass Spec solution to transform mass spectrometry diagnostics
    • 12.3.2. VION Biosciences acquired Ansh Labs enhances global diagnostic capabilities
    • 12.3.3. Bio-Rad launches first ultrasensitive multiplexed digital PCR assay
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Asuragen, Inc. by Bio-Techne Corporation
  • 4. Becton, Dickinson and Company
  • 5. Bio-Rad Laboratories Inc.
  • 6. bioLytical Laboratories
  • 7. bioMerieux SA
  • 8. Cepheid by Danaher Corporation
  • 9. DiaSorin S.p.A.
  • 10. Enzo Biochem, Inc.
  • 11. Hitachi Ltd.
  • 12. Hoffmann-La Roche AG
  • 13. Hologic Inc.
  • 14. HyTest Ltd.
  • 15. Illumina Inc.
  • 16. Merck KGaA
  • 17. OraSure Technologies, Inc.
  • 18. Ortho Clinical Diagnostics
  • 19. Qiagen N.V.
  • 20. Quidel Corporation
  • 21. Randox Laboratories Ltd.
  • 22. Sekisui Diagnostics, LLC
  • 23. Siemens AG
  • 24. Sysmex Corporation by TOA Corporation
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. DIAGNOSTIC SUBSTANCES MARKET MULTI-CURRENCY
  • FIGURE 2. DIAGNOSTIC SUBSTANCES MARKET MULTI-LANGUAGE
  • FIGURE 3. DIAGNOSTIC SUBSTANCES MARKET RESEARCH PROCESS
  • FIGURE 4. DIAGNOSTIC SUBSTANCES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIAGNOSTIC SUBSTANCES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIAGNOSTIC SUBSTANCES MARKET DYNAMICS
  • TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 266. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 276. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 286. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 296. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 306. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 316. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 326. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-20